RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments.
Breakthroughs in Cancer Immunotherapy: An Overview of T Cell, NK Cell, Mφ, and DC-Based Treatments.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
利用嵌合抗原受体(CAR)T细胞治疗癌症已取得惊人进展,针对造血系统恶性肿瘤的临床试验也已证实其应用价值。但该疗法仍有缺点需要解决,包括费用高以及移植物抗宿主病(GvHD)、细胞因子释放综合征(CRS)等副作用。因此,近期研究开始利用不同免疫细胞的特性治疗癌症,不仅包括T细胞,也包括自然杀伤(NK)细胞、巨噬细胞(Mφ)、树突状细胞(DC)等。本文介绍使用多种免疫细胞的细胞疗法,描述其特征和临床研究进展。充分利用每类免疫细胞独特优势开发免疫细胞癌症疗法,有望凭借较高效力和较少副作用改善肿瘤患者生存。
Efforts to treat cancer using chimeric antigen receptor (CAR)-T therapy have made astonishing progress and clinical trials against hematopoietic malignancies have demonstrated their use.
However, there are still disadvantages which need to be addressed: high costs, and side effects such as Graft-versus-Host Disease (GvHD) and Cytokine Release Syndrome (CRS).
Therefore, recent efforts have been made to harness the properties of certain immune cells to treat cancer-not just T cells, but also natural killer (NK) cells, macrophages (M ), dendritic cells (DC), etc. In this paper, we will introduce immune cell-based cellular therapies that use various immune cells and describe their characteristics and their clinical situation.
The development of immune cell-based cancer therapy fully utilizing the unique advantages of each and every immune cell is expected to enhance the survival of tumor patients owing to their high efficiency and fewer side effects.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。